HSBC AKT.ANL. 09/24 SNW/ DE000HS0B0Z7 /
27/05/2024 21:40:09 | Chg.+0.160 | Bid21:58:48 | Ask21:58:48 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
92.890EUR | +0.17% | 92.880 Bid Size: 50,000 |
93.080 Ask Size: 50,000 |
SANOFI SA INHABER ... | 98.00 - | 27/09/2024 | Call |
GlobeNewswire
07:00
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire
21/05
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire
20/05
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
20/05
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
20/05
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire
13/05
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
13/05
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
13/05
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
10/05
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire
08/05
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
07/05
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
02/05
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...